Disitamab vedotin

Generic Name
Disitamab vedotin
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2136633-23-1
Unique Ingredient Identifier
RB3U3A1S27
Background

Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.

Indication

用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌(包括胃食管结合部腺癌)的患者,HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。

Associated Conditions
-
Associated Therapies
-

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-06-22
Last Posted Date
2023-06-22
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
30
Registration Number
NCT05912205

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

First Posted Date
2023-06-22
Last Posted Date
2024-11-13
Lead Sponsor
Seagen Inc.
Target Recruit Count
700
Registration Number
NCT05911295
Locations
🇺🇸

Inova Schar Cancer Institute, Fairfax, Virginia, United States

🇧🇷

Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Other, Brazil

🇧🇷

Centro de Oncologia da Bahia, Salvador, Other, Brazil

and more 113 locations

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

First Posted Date
2023-06-15
Last Posted Date
2023-06-22
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
288
Registration Number
NCT05904964
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

🇨🇳

Hainan Qionghai People's Hospital, Qionghai, Hainan, China

🇨🇳

The Second Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, China

RC48-ADC in Breast Cancer

Recruiting
Conditions
Interventions
First Posted Date
2023-05-10
Last Posted Date
2023-11-21
Lead Sponsor
RenJi Hospital
Target Recruit Count
45
Registration Number
NCT05851677
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

RC48-ADC in HER2-low Advanced Breast Cancer

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2023-04-26
Last Posted Date
2023-05-09
Lead Sponsor
RenJi Hospital
Target Recruit Count
36
Registration Number
NCT05831878
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-02-13
Last Posted Date
2023-02-13
Lead Sponsor
West China Hospital
Target Recruit Count
20
Registration Number
NCT05726175
Locations
🇨🇳

West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

First Posted Date
2022-12-13
Last Posted Date
2022-12-16
Lead Sponsor
Shen Lin
Target Recruit Count
306
Registration Number
NCT05649163
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

First Posted Date
2022-10-19
Last Posted Date
2022-10-19
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
55
Registration Number
NCT05586061
Locations
🇨🇳

Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

🇨🇳

Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan, Shandong, China

🇨🇳

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China

and more 4 locations

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

First Posted Date
2022-08-10
Last Posted Date
2022-08-10
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
176
Registration Number
NCT05495724
Locations
🇨🇳

Tianjin Medical University Second Hospital, Tianjin, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath